Cargando…

PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas

Cancer including melanoma may be “addicted” to double strand break (DSB) repair and targeting this process could sensitize them to the lethal effect of DNA damage. PARP1 exerts an important impact on DSB repair as it binds to both single- and double- strand breaks. PARP1 inhibitors might be highly e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Czyż, Małgorzata, Toma, Monika, Gajos-Michniewicz, Anna, Majchrzak, Kinga, Hoser, Grazyna, Szemraj, Janusz, Nieborowska-Skorska, Margaret, Cheng, Phil, Gritsyuk, Daniel, Levesque, Mitchell, Dummer, Reinhard, Sliwinski, Tomasz, Skorski, Tomasz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342760/ https://www.ncbi.nlm.nih.gov/pubmed/27705909 http://dx.doi.org/10.18632/oncotarget.12270

Ejemplares similares

Histone Deacetylases (HDAC) Inhibitor—Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor
por: Drzewiecka, Małgorzata, et al.
Publicado: (2023)

Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent
por: Toma, Monika, et al.
Publicado: (2018)

AKT-induced reactive oxygen species generate imatinib-resistant clones emerging from chronic myeloid leukemia progenitor cells
por: Nieborowska-Skorska, Margaret, et al.
Publicado: (2014)

Signal Transducer and Activator of Transcription (STAT)5 Activation by BCR/ABL Is Dependent on Intact Src Homology (SH)3 and SH2 Domains of BCR/ABL and Is Required for Leukemogenesis
por: Nieborowska-Skorska, Malgorzata, et al.
Publicado: (1999)

Role of miRNAs in Melanoma Metastasis
por: Gajos-Michniewicz, Anna, et al.
Publicado: (2019)

WNT Signaling in Melanoma
por: Gajos-Michniewicz, Anna, et al.
Publicado: (2020)

WNT/β-catenin signaling in hepatocellular carcinoma: The aberrant activation, pathogenic roles, and therapeutic opportunities
por: Gajos-Michniewicz, Anna, et al.
Publicado: (2023)

RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies
por: Toma, Monika, et al.
Publicado: (2019)

Reactive Oxygen Species and Mitochondrial DNA Damage and Repair in BCR-ABL1 Cells Resistant to Imatinib
por: Blasiak, Janusz, et al.
Publicado: (2015)

ABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemias
por: Golovine, Konstantin, et al.
Publicado: (2023)

Relationship between Oxidative Stress and Imatinib Resistance in Model Chronic Myeloid Leukemia Cells
por: Głowacki, Sylwester, et al.
Publicado: (2021)

Increased phosphorylation of eIF2α in chronic myeloid leukemia cells stimulates secretion of matrix modifying enzymes
por: Podszywalow-Bartnicka, Paulina, et al.
Publicado: (2016)

UV Differentially Induces Oxidative Stress, DNA Damage and Apoptosis in BCR-ABL1-Positive Cells Sensitive and Resistant to Imatinib
por: Synowiec, Ewelina, et al.
Publicado: (2015)

MCL-1, BCL-X(L) and MITF Are Diversely Employed in Adaptive Response of Melanoma Cells to Changes in Microenvironment
por: Hartman, Mariusz L., et al.
Publicado: (2015)

Doxorubicin Differentially Induces Apoptosis, Expression of Mitochondrial Apoptosis-Related Genes, and Mitochondrial Potential in BCR-ABL1-Expressing Cells Sensitive and Resistant to Imatinib
por: Synowiec, Ewelina, et al.
Publicado: (2015)

PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation
por: Mao, Yize, et al.
Publicado: (2018)

Rhaponticum carthamoides transformed root extract inhibits human glioma cells viability, induces double strand DNA damage, H2A.X phosphorylation, and PARP1 cleavage
por: Skała, Ewa, et al.
Publicado: (2018)

Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells
por: Sullivan-Reed, Katherine, et al.
Publicado: (2018)

Pentoxifylline Inhibits WNT Signalling in β-Catenin(high) Patient-Derived Melanoma Cell Populations
por: Talar, Beata, et al.
Publicado: (2016)

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity
por: Hartman, Mariusz L., et al.
Publicado: (2020)

Monoubiquitinated Fanconi Anemia D2 (FANCD2-Ub) Is Required for BCR-ABL1 Kinase -Induced Leukemogenesis
por: Koptyra, Mateusz, et al.
Publicado: (2011)

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
por: Ordóñez, José Luis, et al.
Publicado: (2015)

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
por: Nonnekens, Julie, et al.
Publicado: (2016)

PET Imaging of PARP Expression Using (18)F-Olaparib
por: Wilson, Thomas C., et al.
Publicado: (2019)

Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality
por: Le, Bac Viet, et al.
Publicado: (2022)

Class I HDAC Inhibition Leads to a Downregulation of FANCD2 and RAD51, and the Eradication of Glioblastoma Cells
por: Drzewiecka, Małgorzata, et al.
Publicado: (2023)

Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program
por: Czyz, Malgorzata, et al.
Publicado: (2019)

ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib()
por: Wang, Chen, et al.
Publicado: (2017)

Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib
por: Osoegawa, Atsushi, et al.
Publicado: (2017)

Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
por: Ordóñez, José Luis, et al.
Publicado: (2017)

Olaparib‐Based Photoaffinity Probes for PARP‐1 Detection in Living Cells
por: Voorneveld, Jim, et al.
Publicado: (2020)

PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells
por: Liu, Chuan, et al.
Publicado: (2020)

The Effect of Leonurus sibiricus Plant Extracts on Stimulating Repair and Protective Activity against Oxidative DNA Damage in CHO Cells and Content of Phenolic Compounds
por: Sitarek, Przemysław, et al.
Publicado: (2016)

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
por: Nile, Donna L., et al.
Publicado: (2016)

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
por: Park, Hye Jeong, et al.
Publicado: (2018)

PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation
por: Kageyama, Shun-ichiro, et al.
Publicado: (2020)

Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib
por: Gross, Maya, et al.
Publicado: (2022)

Synthetic Lethality Targeting Polθ
por: Drzewiecka, Małgorzata, et al.
Publicado: (2022)

Polθ Inhibition: An Anticancer Therapy for HR-Deficient Tumours
por: Barszczewska-Pietraszek, Gabriela, et al.
Publicado: (2022)

Gene Expression Profiling Identifies Microphthalmia-Associated Transcription Factor (MITF) and Dickkopf-1 (DKK1) as Regulators of Microenvironment-Driven Alterations in Melanoma Phenotype
por: Hartman, Mariusz L., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ai4gn4vmiv0c233rmujvfbo9vp